title: Comparison of the effects of salmeterol/fluticasone propionate with fluticasone propionate on airway physiology in adults with mild persistent asthma.
abstract: BACKGROUND
  This study compared the effect of inhaled fluticasone propionate (FP) with the combination of salmeterol/fluticasone propionate (SFC) on lung function parameters in patients with mild asthma.
  
  
  METHODS
  Adult patients with mild persistent asthma (> or = 80% predicted FEV1) receiving 200-500 mug of BDP or equivalent were randomised to receive either FP 100 mug or SFC 50/100 mug twice daily from a Diskus inhaler for four weeks. The primary outcome was the change from baseline in airway resistance (sRaw) at 12 hrs post dose measured by whole body plethysmography. Impulse oscillometry and spirometry were also performed.
  
  
  RESULTS
  A comparison of the geometric mean sRaw at 12 hrs post dose in the SFC group to the FP group gave a ratio of 0.76 (0.66 - 0.89, p < 0.001) at week 2 and 0.81 (0.71 - 0.94, p = 0.006) at week 4. Similarly, significant results in favour of SFC for oscillometry measurements of resistance and reactance were observed. FEV1 was also significantly superior at week 2 in the SFC group (mean difference 0.16L, 95% CI; 0.03 - 0.28, p = 0.015), but not at week 4 (mean difference 0.17L, 95% CI -0.01 - 0.34, p = 0.060).
  
  
  CONCLUSIONS
  SFC is superior to FP in reducing airway resistance in mild asthmatics with near normal FEV1 values. This study provides evidence that changes in pulmonary function in patients with mild asthma are detected more sensitively by plethysmography compared to spirometry
  
  
  BACKGROUND
  NCT00370591.
authors.affiliation: North West Lung Research Centre, South Manchester University Hospitals Trust, Manchester, UK. cathhoughton@doctors.org.uk
authors.forename: Catherine M
authors.initials: CM
authors.lastname: Houghton
authors.forename: Naomi
authors.initials: N
authors.lastname: Lawson
authors.forename: Zoe L
authors.initials: ZL
authors.lastname: Borrill
authors.forename: Claire L
authors.initials: CL
authors.lastname: Wixon
authors.forename: Sally
authors.initials: S
authors.lastname: Yoxall
authors.forename: Stephen J
authors.initials: SJ
authors.lastname: Langley
authors.forename: Ashley
authors.initials: A
authors.lastname: Woodcock
authors.forename: Dave
authors.initials: D
authors.lastname: Singh
mesh_terms: D000328:Adult; D000420:Albuterol / Q000008:administration & dosage / Q000031:analogs & derivatives*; D000730:Androstadienes / Q000008:administration & dosage*; D001249:Asthma / Q000188:drug therapy* / Q000503:physiopathology; D004311:Double-Blind Method; D004338:Drug Combinations; D005260:Female; D000068298:Fluticasone; D000068297:Fluticasone-Salmeterol Drug Combination; D005541:Forced Expiratory Volume / Q000187:drug effects / Q000502:physiology; D006801:Humans; D008168:Lung / Q000187:drug effects* / Q000502:physiology*; D008297:Male; D008875:Middle Aged; D012129:Respiratory Function Tests; D012143:Respiratory Physiological Phenomena / Q000187:drug effects
chemical_list: D000730:Androstadienes; D004338:Drug Combinations; D000068297:Fluticasone-Salmeterol Drug Combination; D000068298:Fluticasone; D000420:Albuterol